| Index | — | P/E | 14.00 | EPS (ttm) | 0.24 | Insider Own | — | Shs Outstand | 43.89M | Perf Week | -11.81% |
| Market Cap | 147.47M | Forward P/E | — | EPS next Y | — | Insider Trans | — | Shs Float | 39.69M | Perf Month | -46.58% |
| Enterprise Value | 135.47M | PEG | — | EPS next Q | — | Short Float | 0.08% | Perf Quarter | -68.45% | ||
| Income | 6.00M | P/S | 16.39 | EPS this Y | — | Short Ratio | 0.21 | Perf Half Y | -88.37% | ||
| Sales | 9.00M | P/B | 8.68 | EPS next Y | — | ROA | 28.07% | Short Interest | 31.12K | Perf YTD | -88.83% |
| Book/sh | 0.39 | P/C | 12.29 | EPS next 5Y | — | ROE | 27.49% | 52W High | 44.74 -92.49% | Perf Year | -84.48% |
| Cash/sh | 0.27 | P/FCF | — | EPS past 3/5Y | 31.98% — | ROIC | 25.46% | 52W Low | 3.09 8.74% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | 19.35 | Sales past 3/5Y | -27.89% — | Gross Margin | 86.10% | Volatility | 9.09% 11.78% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 15.05 | EPS Y/Y TTM | 167.61% | Oper. Margin | 65.20% | ATR (14) | 0.51 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 344.31 | Sales Y/Y TTM | -30.77% | Profit Margin | 72.09% | RSI (14) | 29.43 | Recom | — |
| Dividend Gr. 3/5Y | — | Current Ratio | 344.31 | EPS Q/Q | — | SMA20 | -15.10% | Beta | 0.41 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 66.67% | SMA50 | -38.55% | Rel Volume | 0.26 | Prev Close | 3.72 |
| Employees | 27 | LT Debt/Eq | 0.00 | Earnings | Jul 07 | SMA200 | -80.61% | Avg Volume | 152.19K | Price | 3.36 |
| IPO Date | Feb 19, 2025 | Option/Short | No / Yes | EPS/Sales Surpr. | — | Net Debt/EBITDA | -1.71 | Volume | 39,019 | Change | -9.68% |
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 9 | 9 | 8 | 7 | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 2 | 3 | — | — | |
| Gross Profit | 8 | 8 | 6 | 3 | — | — | |
| Selling, General and Administrative Excl. Other | 2 | 2 | 3 | 1 | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | |
| Other Operating Expense | -1 | 0 | 1 | 0 | — | — | |
| Operating Income | 6 | 6 | 2 | 2 | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 1 | 0 | 0 | — | — | |
| Net Income Before Taxes | 6 | 6 | 2 | 2 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | 6 | 6 | 2 | 2 | — | — | |
| Net Income From Continuing Operations | 6 | 6 | 2 | 2 | — | — | |
| Net Income | 6 | 6 | 2 | 2 | — | — | |
| EPS (Recurring) | 0.24 | 0.16 | 0.06 | 0.02 | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.24 | 0.16 | 0.06 | 0.02 | — | — | |
| EPS (Diluted) | 0.24 | 0.16 | 0.06 | 0.01 | — | — | |
| EBITDA | 7 | 6 | 2 | 2 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | 14.00 | 187.94 | — | — | — | — | |
| Price To Sales Ratio | 16.43 | 147.01 | — | — | — | — | |
| Gross Margin | 88.89 | 88.89 | 75.00 | 42.86 | — | — | |
| Operating Margin | 66.67 | 66.67 | 25.00 | 28.57 | — | — | |
| Net Margin | 66.67 | 66.67 | 25.00 | 28.57 | — | — | |
| Shares Outstanding | 44 | 44 | 42 | 144 | — | — | |
| Market Capitalization | 148 | 1,323 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |